Applications of (S)-N-Boc-4-Bromophenylalanine in Industrial Manufacturing

As a leading manufacturer specializing in protected chiral amino acids, we ensure the consistent production and supply of (S)-N-Boc-4-Bromophenylalanine for the most demanding industrial sectors. This material finds its place in highly regulated domains where strict process, regulatory, and traceability requirements must be adhered to throughout downstream manufacturing.

1. Pharmaceutical Peptide Synthesis

Pharmaceutical manufacturers regularly specify this compound as a key protected building block in solid-phase peptide synthesis (SPPS) for research, clinical, and commercial-scale active pharmaceutical ingredient (API) production. Its structural attributes enable selective incorporation in complex custom and catalog peptides aimed at therapeutic use, especially where halogen-substituted aromatic residues impart significant biological activity. QC and regulatory teams rely on its performance during elongation steps, with downstream impact on yield and purity of injectable or oral peptide APIs.

Industry compliance standards

• ICH Q7 (Good Manufacturing Practice for Active Pharmaceutical Ingredients)
• European Pharmacopoeia (Ph. Eur.) monographs (relevant peptides)
• US Pharmacopeia (USP)
• FDA 21 CFR Part 211 (cGMP for Finished Pharmaceuticals)

Typical usage ratio

• 5–12 mol% per full-length peptide, adjusted based on target sequence complexity and residue frequency; formulation scientists determine site-specific loading for each peptide synthesis protocol.

Downstream process integration

• Manual and automated SPPS, used at protected residue assembly steps, with subsequent Boc-deprotection followed by chain elongation and purification (RP-HPLC, lyophilization).

Final product types

• Clinical-grade peptide APIs for endocrine, oncology, and metabolic therapies
• Custom research peptides for preclinical drug discovery
• Pharmaceutical impurity reference standards

2. Small Molecule Drug Intermediate Synthesis

Medicinal chemistry groups and CDMOs apply this material as a key intermediate in the multi-step synthesis of chiral small molecules, specifically where brominated phenylalanine scaffolds serve as pharmacophores or as handles for subsequent cross-coupling. Its Boc-protection allows selective modifications and protects amino functionality during Suzuki, Heck, or Buchwald–Hartwig coupling reactions, contributing to the generation of complex investigational and reference compounds for regulated pharmaceutical projects.

Industry compliance standards

• ICH Q11 (Development and Manufacture of Drug Substances)
• Regulatory agency IND/IMPD intermediate quality documentation
• ISO 9001:2015 certified batch production

Typical usage ratio

• Varies between 0.5–1.2 equivalents per intermediate; ratio determined by reaction stoichiometry and multi-step synthetic design.

Downstream process integration

• Enter API intermediate synthesis at the step requiring protected chiral amino acid; participates in Grignard functionalization, aryl halide cross-coupling, followed by Boc removal and chiral purification (flash chromatography, preparative HPLC).

Final product types

• Chiral intermediates for CNS and anti-infective drug pipelines
• Pharmaceutical reference compounds
• Regulated intermediates for generic drug manufacturing

3. Custom Peptide Probe and Diagnostic Kit Manufacturing

Specialist diagnostic and life science kit manufacturers require reliable incorporation of this bromophenylalanine derivative during synthetic peptide probe production. The protected form guarantees precise residue incorporation to deliver site-specific labeling or as a precursor for further functionalization steps, underpinning the manufacture of diagnostic kits, binding assays, and biomarker quantitation tools—especially where halogen-tagged sequences enhance detection sensitivity.

Industry compliance standards

• ISO 13485:2016 (Quality Management System for Medical Devices and Diagnostics)
• CLSI EP05 (Evaluation of Precision Performance of Quantitative Measurement Methods)
• EU In Vitro Diagnostic Regulation (IVDR 2017/746)

Typical usage ratio

• 1 residue per probe peptide, typically 2–9% of total amino acid sequence, depending on the application’s design for labeling or specificity enhancement.

Downstream process integration

• Incorporated at the designated residue position during automated SPPS; post-assembly, sequences are deprotected, cleaved, optionally functionalized (e.g., radiolabeling, fluorescent tagging), and formulated into kit/assay components.

Final product types

• Oligopeptide diagnostic reagents for ELISA and binding assays
• Labelled peptide probes for immunodiagnostics
• Quantitative reference standards for LC-MS/MS diagnostic workflows

4. Chemical Biology – Halogen-Tag Introduction in Proteomics Tools

(Chemical) proteomics and academic bioanalytical labs use this protected amino acid to introduce a brominated tag into tailored synthetic peptides or peptide-mimetic scaffolds. The functionality enables downstream labeling (e.g., via Suzuki–Miyaura coupling) or serves as a mass signal in quantitation protocols. Researchers depend on its high site specificity and orthogonal protection for experimental workflows involving complex probe design or 'click' chemistry adaptation.

Industry compliance standards

• GLP (Good Laboratory Practice) for reference material and probe synthesis
• Internal ISO/IEC 17025-accredited methods (testing/characterization)
• Harmonized custom reagent production guidelines (major proteomics centers)

Typical usage ratio

• Range 1–15 mol% in custom peptide probes—percentage and sequence position determined by labeling needs, probe construct length, and detection requirements.

Downstream process integration

• Added at the synthesis step for site-specific halogen tagging; post-synthesis processing may involve further chemical functionalization, purification, and formulation into analytical kits or standards.

Final product types

• Halogenated reference peptides for proteomic mass spectrometry
• Synthetic peptide standards for quantitative bioanalysis
• Specialty labeling tools for academic and industrial chemical biology research

5. Active Ingredient in Research-Grade Peptidomimetic Libraries

Library synthesis operations for early-stage drug discovery projects incorporate this chiral building block to expand the diversity of peptidomimetics. Halogenated phenylalanine motifs open up routes for high-throughput screening of non-natural ligands, and the Boc group provides controllable deprotection for further derivatization. Our production supports large batch requirements where each compound in the library must meet stringent traceability, chemical purity, and batch consistency benchmarks demanded by institutional and biotech R&D groups.

Industry compliance standards

• NIH guidelines for chemical library synthesis in academic consortia
• Institutional chemical safety and use protocols
• ISO 9001:2015 process documentation for traceability

Typical usage ratio

• Typically 3–8 mol% per compound synthesized within combinatorial libraries, based on library design and targeted residue positions for SAR studies.

Downstream process integration

• Initiates incorporation during solid or solution-phase peptide and peptidomimetic assembly, with subsequent analytical validation, splitting and mixing for diversity, and structural confirmation (NMR, LC-MS).

Final product types

• Combinatorial libraries for high-throughput screening
• Lead identification candidates for pharma and biotech R&D
• Bioactive peptidomimetic reference sets